{"pageContent": "Context: Optimal management for patients with intermediate-risk (IR) prostate cancer (PCa) remains controversial. Clinical metrics provide guidance on appropriate management options.", "metaData": {"source": "Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression\nhttps://pubmed.ncbi.nlm.nih.gov/7357521/"}}